EH301

[Jean-Pierre Le Rouzic]

There are many drugs that were granted the status of orphan drugs for ALS by FDA. But for most it was retracted later.

And this clinical trial EH30 is quite controversial. Please look at the comments in:
https://www.alzforum.org/news/research-news/small-trial-eh301-appears-halt-progression-als

Three of the authors of this study received stock options from Elysium Health, the company that owns EH301.

My own remark would be about several of the authors who did not published previously on neurodegenerative diseases but rather on some strange topics such as:

Bone quality in young adults with intellectual disability involved in adapted competitive football.

or

[EFFECTS OF VOLUNTARY INTAKE OF FLUIDS (WATER AND SPORTS DRINK) IN AMATEUR MOUNTAIN RUNNERS].

or even

Effect of moderate high temperature on the vegetative growth and potassium allocation in olive plants.

 

That looks like very impressive qualifications for participating in a breakthrough research on ALS!

 

 

[Brett]

Thanks Jean-Pierre.  Despite the questionable expertise of some of the authors, the clinical trial did seem to show some positive outcomes, and the Mayo Clinic has apparently bought into it, maybe there is something there.  I guess the rigor of a Phase II/III clinical trial will prove if there’s something to it.

[Dagmar]

One more drug/supplement to keep an eye on – – maybe holds potential? Or, maybe just good backstory drama that could be the next Netflix series… 😉